Dr. Reshma Mahtani, from Miami Cancer Institute, highlights recent updates to national oncology practice guidelines regarding extension of endocrine therapy beyond 5 years, the data supporting these updates, and their impact on clinical practice. Participants will learn about strategies to help avoid under- and over-treatment and optimize recommendations related to treatment duration.
Sponsored by Biotheranostics, Inc., A Hologic Company. Reshma Mahtani, DO is a consultant of Biotheranostics.
Негізгі бет Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast Cancer
Пікірлер